Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with Adebrelimab and Apatinib for HCC
NCT06538935Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University Cancer Hospital. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06538935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538935.